Related Benzinga's Option Alert Recap From August 4 Report Says Google Was Once Interested In Acquiring Snap Last Year Related GS Analyst Thinks Lending Club Deserves More Credit, Upgrades To Outperform BMO Capital Says It's Closing The Pair Trade On Wells Fargo And Citigroup US Market Indexes....More>>>
Some analysts cite Hillary Clinton’s continued criticism of drug prices as a cause for a slump in biotech during the U.S. presidential campaign, but with the election behind us, many biotech enterprises saw at least a 9% increase due to Donald Trump’s victory.
Two companies in the biotech space entering the first quarter of 2017 may be in a position for their products, as well....More>>>
On Thursday, our Elite Opportunity Pronewsletter suggested getting into Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA: LABU) in part totake advantage of the January effect:
As a matter of fact, the entire biotech sector was the big performer yesterday, so we’re going to go ahead and take another shot with LABU, one of the primary bullish leveraged ETF’s tracking the....More>>>
Shares of Inovio Pharmaceuticals(INO) are climbing today after the biotech company announced that it would begin testing a Zika vaccine in Puerto Rico. Maxim’sJason McCarthy andJason Kolbert have the details:
CREDIT: Alex Wild Published Credit: Alex Wild Alex Wild
Inovio announced the initiation of a small clinical study (N=160) of its Zika vaccine, GLS-5700 (being developed....More>>>
ImmunoGen (NASDAQ:IMGN) is up 21.8% at 1:06 p.m. EST on no apparent news. Of course, it’s a biotech, so that’s often par for the course.
One possibility is that day traders are just doing their thing, following the momentum, which pushes the stock price higher. We’ll know in a few days if the share price returns to previous levels.
Welcome to another edition of “3 Things in Biotech You Should Learn Today,” a daily digest dedicated to helping you keep tabs on the fast-moving world of biotech and pharmaceutical research.
Let’s get started!
AstraZeneca whiplash continues with more durvalumab news
In a scrambling defense of disappointing MYSTIC results for its immune checkpoint inhibitor....More>>>
U.S. stocks reversed direction to close mostly lower Thursday as weak financials and consumer staples shares eclipsed a rally in the health-care and biotechnology sectors.
The S&P 500 ....More>>>
March has been a month associated with bad news. Remember Julius Caesar and the ides of March? At least Julius had the opportunity to enjoy a couple of good weeks before disaster struck.
Bad news came early in the month for Juno Therapeutics (NASDAQ:JUNO) and PTC Therapeutics (NASDAQ:PTCT). Both companies announced major pipeline setbacks. What’s next for these beleaguered biotechs?
Shares of Control4 (NASDAQ:CTRL), a leading provider of automation and networking systems for homes and businesses that boasts products to personalize control of music, video, lighting, comfort, security, and communications as an entire premium smart home system, are soaring 20% higher on Friday as of 1:40 p.m. EST.
The surge in price was fueled by the company’s....More>>>
Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep up with recent events in the biotech and pharmaceutical industries!
So what’s in store for today?
BioMarin makes itself a priority to the FDA in phenylketonuria
Phenylketonuria is a congenital disorder that can lead to severe complications....More>>>
ImmunoGen (NASDAQ:IMGN) is up 15.6% at 3:35 p.m. EDT on no news. The stock price bump might be a carryover from yesterday’s upgrade by Leerink Partners. Or maybe it’s short-sellers buying to cover their shorts after yesterday’s move. Or maybe it’s just because it’s a biotech and the sun came up today. Who knows?
We are coming into the fall and the third quarter, aftera surprisingly solid push fromthe markets over the summer. Analysts may say it isnt fundamentally sound but that does not detract from the gains. The high valuations, low volatility, no sell in May and go away and even weak economic data and earnings seem immaterial at this point.
The bull market is now over seven years old. Still, the....More>>>
Struggling to find an acceptable return in this low rate environment? Need more safe healthcare exposure to ballast against the recent pullback in all things biotech-related?
Despite not paying dividends before 2011, Amgen (NASDAQ:AMGN) has since quadrupled its payout and may be just the stock you are looking for.
Let’s take a look at Amgen and see if this....More>>>
Donald Trump’s comments yesterday about the drug industry when he stated that drug companies were “getting away with murder” tanked biotech stocks and the general indexes. Investors in this space must be worried in the event that Trump gains some traction in this sector and records some wins. At present, he is like a dog with a bone. In the automotive sector, for example, he is....More>>>
Monday was a good start to the week for stocks, with major benchmarks climbing around half a percent on the day. Most market participants pointed to a lack of bad news over the weekend and anticipation about expected favorable economic data in the coming days as drivers of the generally positive attitude among investors.
But there are still plenty of factors that are preventing stocks overall....More>>>